2019

  • IVI transitions to an independent non-profit membership organization, governed by a Board of Directors.
  • Release of IVI’s second OSVP disease-specific HTA model, addressing non-small cell lung cancer (NSCLC).
  • IVI is selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award.